109 Diagnostic utility of molecular and imaging biomarkers 2 malignant (TP+FN/ni) sensitivity (95% CI), % specificity (95% CI), % LR+ (95% CI) LR- (95% CI) 21% 14 (0-58) 100 (87-100) 10.50 (0.47-233.70) 0.83 (0.59-1.16) 5% 9 (1-29) 100 (95-100) 16.09 (0.80-323.15) 0.90 (0.78-1.04) 45% 44 (14-79) 100 (40-100) 4.50 (0.30-68.13) 0.61 (0.32-1.15) 15% 72 (47-90) 100 (85-100) 32.68 (2.08-514.60) 0.30 (0.15-0.60) 22% 26 (11-46) 100 (96-100) 53.04 (3.12-900.34) 0.74 (0.59-0.92) 6% 38 (9-76) 100 (95-100) 60.67 (3.40-1,082.61) 0.62 (0.37-1.04) 18% 0 (0-18) 100 (91-100) 1.90 (0.04-92.22) 0.99 (0.91-1.07) 21.3% 19.7 (13.3-28.0) 99.9 (99.3-100) 195.22 (28.77-1,324.65) 0.80 (0.73-0.88) Forest plots showing the estimated pooled sensitivity, specificity, positive and negative likelihood ratios with their corresponding 95% confidence intervals of BRAF mutation analysis in indeterminate thyroid nodules with available histopathological follow-up. CI, confidence interval; df, degrees of freedom; DLR positive, positive diagnostic likelihood ratio; DLR negative, negative diagnostic likelihood ratio; I2, heterogeneity statistic I2; Q, Cochran’s Q.
RkJQdWJsaXNoZXIy MTk4NDMw